Efficacy, Safety and Tolerability of Tegaserod in Patients With Chronic Constipation [clinicaltrials:NCT00149877]

Bio2RDF uri

Efficacy, Safety and Tolerability of Tegaserod in Patients With Chronic Constipation [clinicaltrials:NCT00149877]

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

http://bio2rdf.org/clinicaltrials:NCT00149877

Bio2RDF identifier

NCT00149877

http://www.w3.org/2001/XMLSchema#string

Bio2RDF namespace

clinicaltrials

http://www.w3.org/2001/XMLSchema#string

Bio2RDF uri

http://bio2rdf.org/clinicaltrials:NCT00149877

http://www.w3.org/2001/XMLSchema#string

identifiers.org URI

NCT00149877

authority [clinicaltrials_vocabulary:authority]

clinicaltrials_resource:245b0106e3be1922b847a6799a540c10

brief summary [clinicaltrials_vocabulary:brief-summary]

Tegaserod (HTF919) is a ...... ts in patients with CC.

http://www.w3.org/2001/XMLSchema#string

brief title [clinicaltrials_vocabulary:brief-title]

Efficacy, Safety and Tolerability of Tegaserod in Patients With Chronic Constipation

http://www.w3.org/2001/XMLSchema#string

clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

Number of complete spontaneous bowel movement (csbm) during the first 4 weeks of treatment. [clinicaltrials_resource:3aa59a0406cede0819167993b9902f8e]

clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

Number of complete spontaneous bowel movement (csbm) during the first 4 weeks of treatment. [clinicaltrials_resource:2b6f61ebfee1633090cd0f9bb2620dc5]

Number of complete spontaneous bowel movement (csbm) during the first 4 weeks of treatment. [clinicaltrials_resource:8a7b6b681f2c5e4cd56fcdc3ea27654e]

Number of complete spontaneous bowel movement (csbm) during the first 4 weeks of treatment. [clinicaltrials_resource:9a9d9726269d9d89b183f9e71756430c]

Number of complete spontaneous bowel movement (csbm) during the first 4 weeks of treatment. [clinicaltrials_resource:aa2acdde6ac89f9244b6bc1accedb671]

Number of complete spontaneous bowel movement (csbm) during the first 4 weeks of treatment. [clinicaltrials_resource:fef392385afc256a183b0ac5782b1b0c]

completion date [clinicaltrials_vocabulary:completion-date]

2006-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

download date [clinicaltrials_vocabulary:download-date]

ClinicalTrials.gov processed this data on August 10, 2015

http://www.w3.org/2001/XMLSchema#string

eligibility [clinicaltrials_vocabulary:eligibility]

eligibility for clinicaltrials:NCT00149877 [clinicaltrials_resource:4193e6c317e29c8d0f0be98f54cf991c]

enrollment [clinicaltrials_vocabulary:enrollment]

250

http://www.w3.org/2001/XMLSchema#integer

firstreceived date [clinicaltrials_vocabulary:firstreceived-date]

2005-09-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

has expanded access [clinicaltrials_vocabulary:has-expanded-access]

http://www.w3.org/2001/XMLSchema#string

intervention [clinicaltrials_vocabulary:intervention]

Tegaserod [clinicaltrials_resource:8f4a7ec2f88b8061fda31222527360cd]

intervention browse [clinicaltrials_vocabulary:intervention-browse]

Tegaserod [clinicaltrials_resource:c9a371dd6bd242d8f793562c0011f4ac]

keyword [clinicaltrials_vocabulary:keyword]

Chronic constipation, tegaserod

http://www.w3.org/2001/XMLSchema#string

lastchanged date [clinicaltrials_vocabulary:lastchanged-date]

2008-01-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

lead sponsor [clinicaltrials_vocabulary:lead-sponsor]

Novartis [clinicaltrials_resource:4b711ffdbe8af5c8f3f9c53da46d83fa]

location [clinicaltrials_vocabulary:location]

Novartis [clinicaltrials_resource:620b39a6ec4f160cc195e448be24ea89]

nct id [clinicaltrials_vocabulary:nct-id]

NCT00149877

http://www.w3.org/2001/XMLSchema#string

official title [clinicaltrials_vocabulary:official-title]

Efficacy, Safety and Tolerability of Tegaserod in Patients With Chronic Constipation

http://www.w3.org/2001/XMLSchema#string

org study id [clinicaltrials_vocabulary:org-study-id]

CHTF919EHK01

http://www.w3.org/2001/XMLSchema#string

overall official [clinicaltrials_vocabulary:overall-official]

Novartis [clinicaltrials_resource:bc5de8cd415f4cb7172c4f57b2fb6902]

overall status [clinicaltrials_vocabulary:overall-status]

Completed [clinicaltrials_resource:07ca5050e697392c9ed47e6453f1453f]

oversight [clinicaltrials_vocabulary:oversight]

China: Food and Drug Administration [clinicaltrials_resource:c7a9e75495ed866768e97b10c53c1472]

phase [clinicaltrials_vocabulary:phase]

Phase 4 [clinicaltrials_resource:ec41833bc88cd90619c4d85c549688bd]

source [clinicaltrials_vocabulary:source]

Novartis [clinicaltrials_resource:4b711ffdbe8af5c8f3f9c53da46d83fa]

start date [clinicaltrials_vocabulary:start-date]

2004-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

study design [clinicaltrials_vocabulary:study-design]

clinicaltrials:NCT00149877 study design [clinicaltrials_resource:e25501eb3a00e8e53822184a988f352f]

study type [clinicaltrials_vocabulary:study-type]

Interventional [clinicaltrials_resource:843ac00ae5d0b7c7defb84fb42c2ce31]

url [clinicaltrials_vocabulary:url]

NCT00149877

verification date [clinicaltrials_vocabulary:verification-date]

2008-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

identifier

clinicaltrials:NCT00149877

http://www.w3.org/2001/XMLSchema#string

title

Efficacy, Safety and Tolerability of Tegaserod in Patients With Chronic Constipation

@en

inDataset

clinicaltrials_resource:bio2rdf.dataset.clinicaltrials.R3

type

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

label

Efficacy, Safety and Tolerabil ...... n [clinicaltrials:NCT00149877]

@en